NAACCR Item #3938: ALK Rearrangement

Item # Length Source of Standard Year Implemented Version Implemented Year Retired Version Retired
3,938 1 NAACCR 2021 21

NAACCR XML: Tumor.alkRearrangement


Testing for ALK rearrangement is performed for patients with advanced non-small cell lung cancer (NSCLC) to identify tumors which are sensitive to small-molecule ALK kinase inhibitors.


ALK rearrangement is recommended by treatment guidelines for patients with advanced lung cancer as a prognostic marker and factor in determining appropriate therapy. It is a new data item for cases diagnosed 01/01/2021+.


0Normal ALK negative Negative for rearrangement, no rearrangement identified, no mutations (somatic) identified, not present, not detected
1Abnormal Rearrangement identified/detected: EML4-ALK, KIF5B-ALK, TFG-ALK, and/or KLC1-ALK
2Rearrangement identified/detected: Other ALK Rearrangement not listed in code 1
4Rearrangement, NOS
7Test ordered, results not in chart
8Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error.
9Not documented in medical record ALK Rearrangement not assessed or unknown if assessed
BlankDiagnosis year is prior to 2021

Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.